Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
Lindqvist
P G
PG
Dahlbäck
B
B
D000740:Anemia / Q000209:etiology; D000925:Anticoagulants / Q000009:adverse effects*; D017985:Dalteparin / Q000009:adverse effects* / Q000627:therapeutic use; D036861:Delivery, Obstetric; D003911:Dextrans / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000150:complications; D006801:Humans; D007902:Length of Stay; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D011644:Puerperal Disorders / Q000453:epidemiology / Q000517:prevention & control; D013548:Sweden / Q000453:epidemiology; D019851:Thrombophilia / Q000188:drug therapy / Q000453:epidemiology; D013927:Thrombosis / Q000453:epidemiology / Q000517:prevention & control*; D014592:Uterine Hemorrhage / Q000139:chemically induced* / Q000150:complications; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D003911:Dextrans; D017984:Enoxaparin; D014859:Warfarin; D017985:Dalteparin